

## ALTERNATIVE AND EFFICIENT DELIVERY METHOD OF SILENCING SEQUENCES FOR THE TREATMENT OF BRAIN DISEASES

### KEYWORDS

Gene Therapy; Extracellular Vesicles; miRNA; Spinocerebellar Ataxia Type 3; Ataxin-3; Intranasal; ExoMotif; MJD; SCA3


### TECHNOLOGY DESCRIPTION

The **first** extracellular vesicles (EVs) as therapeutic vehicles targeting the brain containing engineered miRNA-based silencing sequences to treat Machado-Joseph Disease/Spinocerebellar Ataxia Type 3 (MJD/SCA3) upon daily intranasal administration.

#### Advantages:

- Packaging cell line to continuously produce Engineered EVs
- 5x more delivery due to a specific tropism for neurons
- 2.5-fold enrichment of silencing sequences into EVs due to the presence of ExoMotifs
- Non-invasive administration: Intranasal route

**An alternative and efficient delivery method for miRNAs/Silencing sequences to treat MJD and other brain diseases**



### ADVANTAGES OVER ALTERNATIVE TECHNOLOGIES

- Packaging Cell line to large scale and continuous production of engineered EVs.
  - Engineered EVs or similar vesicles for delivery of silencing sequences:
- No other engineered EVs were used to treat brain disorders until now, namely MJD/SCA3

#### Other methods for delivery of silencing sequences:

- Intranasal (IN) vs intracranial delivery: IN delivery allows multiple administrations
- Intranasal (IN) vs intravenous delivery: IN delivery is a non-invasive route.

### APPLICATIONS

Treatment of Machado-Joseph Disease  
Treatment of other brain disorders

### PATENT SPECIFICATIONS

Reference: PCT/IB2023/060856

Responsible Inventor: [Luís Pereira de Almeida](#) ([Gene and Stem Cell Therapies for the Brain Group](#))

Applicants: University of Coimbra ([Center for Neuroscience and Cell Biology](#))

### CONTACTS

Center for Neuroscience and Cell Biology - [Technology Transfer Office](#)

Catarina Cunha Santos, PhD - TTO

Phone: +351 239 820 190

E-mail: [techtransfer@cnc.uc.pt](mailto:techtransfer@cnc.uc.pt)